$Bristol-Myers Squibb (BMY.US)$ 🔔 FDA Approves Breyanzi as ...
$Bristol-Myers Squibb(BMY.US$ 🔔
FDA Approves Breyanzi as New CAR T Cell Therapy
for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approves Breyanzi as New CAR T Cell Therapy
for Relapsed or Refractory Mantle Cell Lymphoma
⇨ only CAR T cell therapy approved for 4 distinct subtypes of non-Hodgkin lymphoma 🩸
⇨ TRANSCEND NHL 001 trial (MCL cohort) 🧫
» delivered responses in 85.3% of patients with one-time infusion
» delivered responses in 85.3% of patients with one-time infusion
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
